Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600
Debt
Debt-to-Equity Ratio0.07
Current Ratio3.52
Quick Ratio3.16
Price-To-Earnings
Trailing P/E Ratio37.04
Forward P/E Ratio36.12
P/E Growth2.95
Sales & Book Value
Annual Sales$771.40 million
Price / Sales3.96
Cash Flow$1.7718 per share
Price / Cash24.67
Book Value$11.42 per share
Price / Book3.83
Profitability
EPS (Most Recent Fiscal Year)$1.05
Net Income$21.80 million
Net Margins17.67%
Return on Equity9.52%
Return on Assets6.82%
Miscellaneous
Employees2,400
Outstanding Shares69,910,000
Market Cap$3,055.63
Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
How were Myriad Genetics' earnings last quarter?
Myriad Genetics, Inc. (NASDAQ:MYGN) issued its quarterly earnings results on Tuesday, May, 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.04. The business earned $193.50 million during the quarter, compared to analysts' expectations of $188.22 million. Myriad Genetics had a return on equity of 9.52% and a net margin of 17.67%. The firm's revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.27 earnings per share. View Myriad Genetics' Earnings History.
What guidance has Myriad Genetics issued on next quarter's earnings?
Myriad Genetics issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $1.19-1.21 for the period, compared to the Thomson Reuters consensus estimate of $1.15. The company issued revenue guidance of $771-773 million, compared to the consensus revenue estimate of $770.43 million.
What price target have analysts set for MYGN?
10 equities research analysts have issued 12-month target prices for Myriad Genetics' stock. Their forecasts range from $23.00 to $55.00. On average, they anticipate Myriad Genetics' stock price to reach $35.30 in the next twelve months. This suggests that the stock has a possible downside of 19.2%. View Analyst Ratings for Myriad Genetics.
What is the consensus analysts' recommendation for Myriad Genetics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Myriad Genetics stock?
Here are some recent quotes from research analysts about Myriad Genetics stock:
- 1. According to Zacks Investment Research, "Despite weakness in Hereditary Cancer testing revenues, Myriad Genetics exited the third quarter of fiscal 2018 on a promising note. The company observed strong growth in GeneSight, Vectra DA and Prolaris testing revenues. Also, Hereditary Cancer volumes expansion was impressive. Furthermore, we are upbeat about the company seeing growth in new product volumes and success of its Elevate 2020 program. Moreover, the company's latest receipt of manufacturing and marketing approval for its BRACAnalysis Diagnostic System in Japan, buoys optimism. Further, the raised FY18 guidance instills confidence in investors. Accordingly, over the past three months, the company has outperformed its industry. However, the decline in Hereditary cancer testing revenues due to price reductions in long-term contracts, raises a concern. Additionally, currency fluctuations and stiff competition are major headwinds." (5/18/2018)
- 2. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)
Who are some of Myriad Genetics' key competitors?
Some companies that are related to Myriad Genetics include Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC) and Akers Biosciences (AKER).
Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the folowing people:
- Mr. Mark Christopher Capone, Pres, CEO & Director (Age 56)
- Mr. R. Bryan Riggsbee, CFO & Treasurer (Age 47)
- Dr. Jerry S. Lanchbury Ph.D., Chief Scientific Officer (Age 59)
- Mr. Richard M. Marsh Esq., Exec. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Alexander Ford, Pres of Myriad Genetic Laboratories, Inc. (Age 51)
Has Myriad Genetics been receiving favorable news coverage?
News headlines about MYGN stock have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myriad Genetics earned a media sentiment score of 0.24 on Accern's scale. They also gave media coverage about the company an impact score of 44.90 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Myriad Genetics' major shareholders?
Myriad Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (13.52%), Fisher Asset Management LLC (0.17%), Bank of Montreal Can (0.10%), Fox Run Management L.L.C. (0.03%), Municipal Employees Retirement System of Michigan (0.03%) and Amalgamated Bank (0.02%). Company insiders that own Myriad Genetics stock include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.
Which institutional investors are selling Myriad Genetics stock?
MYGN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Bank of Montreal Can and Municipal Employees Retirement System of Michigan. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.
Which institutional investors are buying Myriad Genetics stock?
MYGN stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Hartford Investment Management Co., Fisher Asset Management LLC and Amalgamated Bank. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.
How do I buy shares of Myriad Genetics?
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myriad Genetics' stock price today?
One share of MYGN stock can currently be purchased for approximately $43.71.
How big of a company is Myriad Genetics?
Myriad Genetics has a market capitalization of $3.06 billion and generates $771.40 million in revenue each year. The company earns $21.80 million in net income (profit) each year or $1.05 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.
How can I contact Myriad Genetics?
Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]
MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
